跳至主要内容
临床试验/ACTRN12617000935336
ACTRN12617000935336已完成未知

In adults planned to begin treatment with 12 weeks of Sofosbuvir/Ledipasvir for Genotype 1 hepatitis C virus infection, or Sofosbuvir/Daclatasvir for genotype 3 hepatitis C, does minimal monitoring lead to a similar chance of cure with reduced staff time and good patient acceptability compared to a current standard monitoring regimen?

Royal Darwin Hospital0 个研究点目标入组 100 人开始时间: 2017年6月28日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 —(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

招募中
不适用
Phase I Study to Evaluate Safety and Pharmacodynamics of Investigational Product (VT-Tri) after Allogeneic Stem Cell Transplantation in Patients with relapsed/refractory Acute Myeloid Leukemia (AML)
KCT0007025ViGenCell9
进行中(未招募)
1 期
A 12-week, Multicenter, Active-treatment Extension Trial to check how safe, tolerable and effective Brexpiprazole is in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type
EUCTR2018-002783-88-HUOtsuka Pharmaceutical Development & Commercialization, Inc.250
进行中(未招募)
1 期
A 12-week, Multicenter, Active-treatment Extension Trial to check how safe, tolerable and effective Brexpiprazole is in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s TypeAgitation Associated With Dementia of the Alzheimer's TypeMedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders
EUCTR2018-002783-88-ESOtsuka Pharmaceutical Development & Commercialization, Inc.225
进行中(未招募)
1 期
A 12-week, Multicenter, Active-treatment Extension Trial to check how safe, tolerable and effective Brexpiprazole is in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type
EUCTR2018-002783-88-SKOtsuka Pharmaceutical Development & Commercialization, Inc.250
进行中(未招募)
1 期
A 12-week, Multicenter, Active-treatment Extension Trial to check how safe, tolerable and effective Brexpiprazole is in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s TypeAgitation Associated With Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2018-002783-88-BGOtsuka Pharmaceutical Development & Commercialization, Inc.250